This study is currently not recruiting participants.

Safety of Sildenafil in Premature Infants at Risk of Bronchopulmonary Dysplasia

Investigating the Safety of an Investigational Medication in Premature Infants with Risk of Lung Disease

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The purpose of this study is to describe the safety of sildenafil in premature infants at risk of Bronchopulmonary Dysplasia (BPD).

Detailed description of study

The purpose of this study is to describe the safety of sildenafil in premature infants at risk of Bronchopulmonary Dysplasia (BPD).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Bronchopulmonary Dysplasia
  • Age: 100 years or below
  • Gender: All

The purpose of this study is to describe the safety of an investigational medication in premature infants who are at risk of developing Bronchopulmonary Dysplasia (BPD). BPD is a serious lung condition that affects newborns, especially those born prematurely, and involves the abnormal development of lung tissue.

In this study, participants will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will monitor the infants for any side effects or health changes to understand the medication's safety profile.

  • Who can participate: Premature infants who are at risk of developing Bronchopulmonary Dysplasia (BPD) and meet specific age criteria are eligible to participate.
  • Study details: Participants will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine.
Updated on 19 Feb 2024. Study ID: 1802068007

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team